Generic companies planning to market biosimilar medicines in Australia will have to apply to the World Health Organization for a unique INN identifying code, and all biosimilars will have to have a clearly distinguishable trade name, according to guidance just published by the Therapeutic Goods Administration (TGA).
This is the first time that advice on biosimilars has been issued in the form of a guideline, the TGA...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)



